Wegovy Injection Gets Major Delivery Boost from EMA Update

The European Medicines Agency has approved a key update for Wegovy, giving the treatment more flexibility during delivery.

The decision allows Wegovy injections from Novo Nordisk to be kept at temperatures up to 30°C for as long as 48 hours in the final stage of distribution.

This makes Wegovy the first GLP-1 weight management therapy in Europe with this level of delivery flexibility.

Until now, Wegovy had to stay within a strict cold chain from manufacturing to patient use. With this update, pharmacies and online providers can deliver Wegovy without full refrigeration during the last leg, easing logistics and potentially cutting costs. The change could also reduce packaging needs, making shipments lighter and more efficient.

Also Read: Consumer Trust in OTC Products: The Science Behind Safety

Novo Nordisk says the move supports the rise of home delivery for medicines. “Home delivery of medicines is growing rapidly, given the convenience of being able to receive your medicines at your doorstep, which we have come to expect from most other aspects of our lives,” said Mike Doustdar, CEO and president of Novo Nordisk.

“People with obesity using prescription medicine may also face stigma, and we are therefore excited about the opportunity to reduce distribution complexity while further enabling discrete home delivery options,” he added.

The update applies only to healthcare providers through revised product information. There is no change for patients. After first use, Wegovy can still be stored for up to 28 days below 30°C or kept refrigerated.

Wegovy continues to expand its role in obesity care, with approvals across major markets. The injectable form is widely authorized, while the oral version is still under review in Europe and expected later in 2026.